Mankind Pharma share price
You have to be logged in to add this to Watchlist.- ₹2,582.65(2.39%)April 17, 2025 15:42:16 PM IST
- NSE
- BSE
- Vol : 509.03K (NSE + BSE)Last 20 day avg : 644.40 K
Mankind Pharma is trading 2.39% upper at Rs 2,582.65 as compared to its last closing price. Mankind Pharma has been trading in the price range of 2,600.00 & 2,505.00. Mankind Pharma has given -10.37% in this year & 9.97% in the last 5 days. Mankind Pharma has TTM P/E ratio 56.58 as compared to the sector P/E of 29.14.There are 13 analysts who have initiated coverage on Mankind Pharma. There are 4 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 380.23 Crores in its last quarter.Listed peers of Mankind Pharma include Hyundai Motor India (1.62%), Bajaj Housing Finance (-0.77%), Mankind Pharma (2.39%).The Mutual Fund holding in Mankind Pharma was at 7.67% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Mankind Pharma was at 12.92% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 20, 2025, 07:37 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/B11.05The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values50.79Price-to-earnings ratio based on trailing 12-month earnings
- Debt To EquityHigher than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable- The company's profit declined by 16.20% year-on-year during the December quarter, dropping from Rs 453.76 crore to Rs 380.23 crore
- The debt to equity of the company is higher than the industry median
Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,584.05
- R2
- 2,744.95
- R3
- 2,889.90
- S1
- 2,278.20
- S2
- 2,133.25
- S3
- 1,972.35
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Hyundai Motor India | Neutral | 1,663.50 | 1.62 | 1,35,166.21 | 22.30 | 12.66 | - | 6.36 |
| Bajaj Housing Finance | Bullish | 128.75 | -0.77 | 1,07,224.89 | 48.51 | 7.06 | - | 563.92 |
| Mankind Pharma | Bullish | 2,582.65 | 2.39 | 1,06,554.59 | 54.17 | 11.05 | - | 0.35 |
| Ntpc Green Energy | Neutral | 108.30 | 2.41 | 91,257.15 | 264.57 | 14.64 | - | 210.89 |
| Swiggy | Neutral | 340.95 | 1.43 | 77,957.57 | - | - | 7.23 |
- Promoter(s) does not have a high stake in the company
- There is no pledging of shares in promoter holding
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-23 | Quarterly Results |
| 2024-11-05 | Quarterly Results |
| 2024-07-31 | Quarterly Results |
| 2024-05-15 | Audited Results & Others |
| 2024-01-31 | Quarterly Results |
- Industry
- ISININE634S01028
- BSE Code543904
- NSE CodeMANKIND
Mankind Pharma is trading at 2582.65 as on Thu Apr 17 2025 10:12:16. This is 2.39% upper as compared to its previous closing price of 2522.45.
The market capitalization of Mankind Pharma is 106554.59 Cr as on Thu Apr 17 2025 10:12:16.
The average broker rating on Mankind Pharma is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 2 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Mankind Pharma is 3050.00 whereas the 52 wk low is 1910.10
Mankind Pharma can be analyzed on the following key metrics -
- TTM P/E: 56.58
- Sector P/E: 29.14
- Dividend Yield: 0.00%
- D/E ratio: -
Mankind Pharma reported a net profit of 1912.90 Cr in 2024.
The Mutual Fund Shareholding was 7.67% at the end of 31 Mar 2025.